Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

First-in-man beta-cell regeneration for causal type 2 diabetes therapy

Ziel

More than 589 million people worldwide suffer from diabetes (IDF atlas 11th edition). Currently, none of the pharmacological therapies can stop disease progression, which leads to devastating micro- and macrovascular complications and a steady increase in patient numbers. Prediabetic individuals develop type 2 diabetes (T2D) when insulin-producing beta-cells in the pancreas become insulin resistant, lose their function and die. Importantly, beta-cells not only produce insulin but also are critically dependent on insulin signaling for their function, survival and compensation upon increased metabolic needs due to gluco/lipotoxicity and insulin resistance. In a breakthrough discovery, we have previously identified a novel and druggable insulin inhibitory receptor (in short: inceptor). Genetic or pharmacological inceptor blockade allows insulin sensitization to enhance beta-cell function, survival, and regeneration, and as such, allows for the first time to revert diabetes progression in T2D mouse models.
Based on this novel therapeutic target and encouraging preclinical findings, we aim to develop a transformative, disease-modifying therapy for diabetes that goes beyond the
symptomatic treatments currently available. The goal of this ERC Proof-of-Concept (PoC) grant is to provide financial, business, developmental and regulatory preparedness for the new spin-off company Viacure Therapeutics GmbH, which plans to make the transition from basic research to preclinical and clinical development to implement first-in-class beta-cell regeneration therapy in the clinic, as a first causative treatment for people living with T2D.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Netto-EU-Beitrag
€ 20 000,00
Adresse
INGOLSTADTER LANDSTRASSE 1
85764 Neuherberg
Deutschland
Region
Bayern Oberbayern München, Landkreis
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten

Begünstigte (2)